Annual report
2796.TEDINET S100UB27
Period2023-06-01 → 2024-05-31
Filed2024-08-30
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 157
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥54.5bn | 2023-06-01 → 2024-05-31 | Cons. | Net sales |
| Revenue | ¥52.0bn | 2022-06-01 → 2023-05-31 | Cons. | Net sales |
| Revenue | ¥51.6bn | 2021-06-01 → 2022-05-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥52.3bn | 2020-06-01 → 2021-05-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥51.0bn | 2019-06-01 → 2020-05-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥916m | 2023-06-01 → 2024-05-31 | Cons. | Operating income |
| Operating income | ¥1.4bn | 2022-06-01 → 2023-05-31 | Cons. | Operating income |
| Ordinary income | ¥833m | 2023-06-01 → 2024-05-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.4bn | 2022-06-01 → 2023-05-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.5bn | 2021-06-01 → 2022-05-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.3bn | 2020-06-01 → 2021-05-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.0bn | 2019-06-01 → 2020-05-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥143m | 2023-06-01 → 2024-05-31 | Cons. | Income before income taxes |
| Profit before tax | ¥1.0bn | 2022-06-01 → 2023-05-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥351m | 2023-06-01 → 2024-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥333m | 2022-06-01 → 2023-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥447m | 2021-06-01 → 2022-05-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥426m | 2020-06-01 → 2021-05-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥577m | 2019-06-01 → 2020-05-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥342m | 2023-06-01 → 2024-05-31 | Cons. | Profit loss |
| Net income | ¥347m | 2022-06-01 → 2023-05-31 | Cons. | Profit loss |
| Total assets | ¥29.5bn | at 2024-05-31 | Cons. | Assets |
| Total assets | ¥23.4bn | at 2023-05-31 | Cons. | Assets |
| Total assets | ¥23.7bn | at 2022-05-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥24.7bn | at 2021-05-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥25.2bn | at 2020-05-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥22.0bn | at 2024-05-31 | Cons. | Liabilities |
| Total liabilities | ¥16.4bn | at 2023-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥7.4bn | at 2024-05-31 | Cons. | Net assets |
| Net assets / equity | ¥7.0bn | at 2023-05-31 | Cons. | Net assets |
| Net assets / equity | ¥6.7bn | at 2022-05-31d | Cons. | Net assets |
| Net assets / equity | ¥6.3bn | at 2021-05-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥5.9bn | at 2020-05-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥7.2bn | at 2024-05-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.7bn | at 2023-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥7.1bn | at 2024-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.7bn | at 2023-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.0bn | at 2022-05-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.6bn | at 2021-05-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥4.5bn | at 2020-05-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥2.7bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.5bn | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥713m | 2021-06-01 → 2022-05-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.9bn | 2020-06-01 → 2021-05-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.6bn | 2019-06-01 → 2020-05-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥3.1bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥703m | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥292m | 2021-06-01 → 2022-05-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.1bn | 2020-06-01 → 2021-05-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥734m | 2019-06-01 → 2020-05-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥2.8bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.1bn | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.0bn | 2021-06-01 → 2022-05-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥728m | 2020-06-01 → 2021-05-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥766m | 2019-06-01 → 2020-05-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-33.41 | 2023-06-01 → 2024-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥35.45 | 2022-06-01 → 2023-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥47.99 | 2021-06-01 → 2022-05-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥45.83 | 2020-06-01 → 2021-05-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥61.11 | 2019-06-01 → 2020-05-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥26.89 | 2022-06-01 → 2023-05-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥36.29 | 2021-06-01 → 2022-05-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥34.64 | 2020-06-01 → 2021-05-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥46.38 | 2019-06-01 → 2020-05-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥636.25 | at 2024-05-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥708.01 | at 2023-05-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥684.2 | at 2022-05-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥646.66 | at 2021-05-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥613.2 | at 2020-05-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 24.3% | at 2024-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.5% | at 2023-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 26.9% | at 2022-05-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 24.3% | at 2021-05-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 22.6% | at 2020-05-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | -5.1% | 2023-06-01 → 2024-05-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.1% | 2022-06-01 → 2023-05-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.2% | 2021-06-01 → 2022-05-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.3% | 2020-06-01 → 2021-05-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 10.5% | 2019-06-01 → 2020-05-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,848 | at 2024-05-31 | Cons. | Number of employees |
| Employees | 1,555 | at 2023-05-31 | Cons. | Number of employees |
| Employees | 1,544 | at 2022-05-31d | Cons. | Number of employees |
| Employees | 1,546 | at 2021-05-31d | Cons. | Number of employees |
| Employees | 1,555 | at 2020-05-31d | Cons. | Number of employees |
| Revenue | ¥1.1bn | 2023-06-01 → 2024-05-31 | Standalone | Net sales |
| Revenue | ¥1.3bn | 2022-06-01 → 2023-05-31 | Standalone | Net sales |
| Revenue | ¥1.3bn | 2021-06-01 → 2022-05-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.4bn | 2020-06-01 → 2021-05-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.2bn | 2019-06-01 → 2020-05-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥28m | 2023-06-01 → 2024-05-31 | Standalone | Operating income |
| Operating income | ¥317m | 2022-06-01 → 2023-05-31 | Standalone | Operating income |
| Ordinary income | ¥1.1bn | 2023-06-01 → 2024-05-31 | Standalone | Ordinary income |
| Ordinary income | ¥415m | 2022-06-01 → 2023-05-31 | Standalone | Ordinary income |
| Ordinary income | ¥406m | 2021-06-01 → 2022-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥428m | 2020-06-01 → 2021-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥378m | 2019-06-01 → 2020-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥1.0bn | 2023-06-01 → 2024-05-31 | Standalone | Income before income taxes |
| Profit before tax | ¥158m | 2022-06-01 → 2023-05-31 | Standalone | Income before income taxes |
| Net income | ¥1.0bn | 2023-06-01 → 2024-05-31 | Standalone | Profit loss |
| Net income | ¥82m | 2022-06-01 → 2023-05-31 | Standalone | Profit loss |
| Net income | ¥122m | 2021-06-01 → 2022-05-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥320m | 2020-06-01 → 2021-05-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥264m | 2019-06-01 → 2020-05-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥19.4bn | at 2024-05-31 | Standalone | Assets |
| Total assets | ¥14.1bn | at 2023-05-31 | Standalone | Assets |
| Total assets | ¥14.6bn | at 2022-05-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥14.9bn | at 2021-05-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥15.6bn | at 2020-05-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥12.7bn | at 2024-05-31 | Standalone | Liabilities |
| Total liabilities | ¥9.3bn | at 2023-05-31 | Standalone | Liabilities |
| Net assets / equity | ¥6.7bn | at 2024-05-31 | Standalone | Net assets |
| Net assets / equity | ¥4.8bn | at 2023-05-31 | Standalone | Net assets |
| Net assets / equity | ¥4.8bn | at 2022-05-31d | Standalone | Net assets |
| Net assets / equity | ¥4.8bn | at 2021-05-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥4.6bn | at 2020-05-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.1bn | at 2024-05-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥859m | at 2023-05-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥98.47 | 2023-06-01 → 2024-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥8.77 | 2022-06-01 → 2023-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥13.11 | 2021-06-01 → 2022-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥34.39 | 2020-06-01 → 2021-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥27.94 | 2019-06-01 → 2020-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥94.3 | 2023-06-01 → 2024-05-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥6.78 | 2022-06-01 → 2023-05-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥10.03 | 2021-06-01 → 2022-05-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥26.03 | 2020-06-01 → 2021-05-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥21.29 | 2019-06-01 → 2020-05-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥20 | 2023-06-01 → 2024-05-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥14 | 2022-06-01 → 2023-05-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥14 | 2021-06-01 → 2022-05-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥14 | 2020-06-01 → 2021-05-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥14 | 2019-06-01 → 2020-05-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥577.28 | at 2024-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥488.13 | at 2023-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥492.05 | at 2022-05-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥490.97 | at 2021-05-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥470.21 | at 2020-05-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 33.5% | at 2024-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.7% | at 2023-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.6% | at 2022-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.7% | at 2021-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.0% | at 2020-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 18.7% | 2023-06-01 → 2024-05-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.8% | 2022-06-01 → 2023-05-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.7% | 2021-06-01 → 2022-05-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.2% | 2020-06-01 → 2021-05-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.1% | 2019-06-01 → 2020-05-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 12,060,381 | at 2024-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 9,746,645 | at 2023-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 9,673,785 | at 2022-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 9,615,515 | at 2021-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 9,560,655 | at 2020-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 64 | at 2024-05-31 | Standalone | Number of employees |
| Employees | 64 | at 2023-05-31 | Standalone | Number of employees |
| Employees | 60 | at 2022-05-31d | Standalone | Number of employees |
| Employees | 33 | at 2021-05-31d | Standalone | Number of employees |
| Employees | 35 | at 2020-05-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 93
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2023-06-01 → 2024-05-31 | ¥134m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2023-06-01 → 2024-05-31 | ¥67m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2024-05-31 | 79 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-06-01 → 2024-05-31 | ¥834m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-06-01 → 2024-05-31 | ¥834m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2024-05-31 | ¥1.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-06-01 → 2024-05-31 | −¥5m |
| Reconciling Itemsreconciling | segment assets | at 2024-05-31 | ¥45m |
| Reconciling Itemsreconciling | segment profit | 2023-06-01 → 2024-05-31 | −¥329m |
| Cosmetic Drug And Convenience Storereportable segment | capex | 2023-06-01 → 2024-05-31 | ¥13m |
| Cosmetic Drug And Convenience Storereportable segment | depreciation | 2023-06-01 → 2024-05-31 | ¥39m |
| Cosmetic Drug And Convenience Storereportable segment | employees | at 2024-05-31 | 119 pure |
| Cosmetic Drug And Convenience Storereportable segment | revenue | 2023-06-01 → 2024-05-31 | ¥8.3bn |
| Cosmetic Drug And Convenience Storereportable segment | revenue external | 2023-06-01 → 2024-05-31 | ¥8.3bn |
| Cosmetic Drug And Convenience Storereportable segment | segment assets | at 2024-05-31 | ¥1.8bn |
| Cosmetic Drug And Convenience Storereportable segment | segment profit | 2023-06-01 → 2024-05-31 | −¥50m |
| Custody Of Medical Documentsreportable segment | capex | 2023-06-01 → 2024-05-31 | ¥15m |
| Custody Of Medical Documentsreportable segment | depreciation | 2023-06-01 → 2024-05-31 | ¥41m |
| Custody Of Medical Documentsreportable segment | employees | at 2024-05-31 | 31 pure |
| Custody Of Medical Documentsreportable segment | revenue | 2023-06-01 → 2024-05-31 | ¥664m |
| Custody Of Medical Documentsreportable segment | revenue external | 2023-06-01 → 2024-05-31 | ¥664m |
| Custody Of Medical Documentsreportable segment | segment assets | at 2024-05-31 | ¥1.6bn |
| Custody Of Medical Documentsreportable segment | segment profit | 2023-06-01 → 2024-05-31 | ¥91m |
| Dispensing Pharmacyreportable segment | capex | 2023-06-01 → 2024-05-31 | ¥488m |
| Dispensing Pharmacyreportable segment | depreciation | 2023-06-01 → 2024-05-31 | ¥447m |
| Dispensing Pharmacyreportable segment | employees | at 2024-05-31 | 1408 pure |
| Dispensing Pharmacyreportable segment | revenue | 2023-06-01 → 2024-05-31 | ¥44.2bn |
| Dispensing Pharmacyreportable segment | revenue external | 2023-06-01 → 2024-05-31 | ¥44.2bn |
| Dispensing Pharmacyreportable segment | segment assets | at 2024-05-31 | ¥24.1bn |
| Dispensing Pharmacyreportable segment | segment profit | 2023-06-01 → 2024-05-31 | ¥1.1bn |
| Medical Mallreportable segment | capex | 2023-06-01 → 2024-05-31 | ¥13m |
| Medical Mallreportable segment | depreciation | 2023-06-01 → 2024-05-31 | ¥17m |
| Medical Mallreportable segment | employees | at 2024-05-31 | 20 pure |
| Medical Mallreportable segment | revenue | 2023-06-01 → 2024-05-31 | ¥506m |
| Medical Mallreportable segment | revenue external | 2023-06-01 → 2024-05-31 | ¥506m |
| Medical Mallreportable segment | segment assets | at 2024-05-31 | ¥199m |
| Medical Mallreportable segment | segment profit | 2023-06-01 → 2024-05-31 | ¥113m |
| —segment total | capex | 2023-06-01 → 2024-05-31 | ¥530m |
| —segment total | depreciation | 2023-06-01 → 2024-05-31 | ¥546m |
| —segment total | revenue | 2023-06-01 → 2024-05-31 | ¥53.6bn |
| —segment total | revenue external | 2023-06-01 → 2024-05-31 | ¥53.6bn |
| —segment total | segment assets | at 2024-05-31 | ¥27.7bn |
| —segment total | segment profit | 2023-06-01 → 2024-05-31 | ¥1.3bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-06-01 → 2024-05-31 | ¥664m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-06-01 → 2024-05-31 | ¥613m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-06-01 → 2024-05-31 | ¥54.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-06-01 → 2024-05-31 | ¥54.5bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-05-31 | ¥29.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-06-01 → 2024-05-31 | ¥1.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2022-06-01 → 2023-05-31 | ¥108m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2022-06-01 → 2023-05-31 | ¥42m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-06-01 → 2023-05-31 | ¥779m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-06-01 → 2023-05-31 | ¥779m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2023-05-31 | ¥2.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-06-01 → 2023-05-31 | ¥36m |
| Reconciling Itemsreconciling | segment assets | at 2023-05-31 | ¥55m |
| Reconciling Itemsreconciling | segment profit | 2022-06-01 → 2023-05-31 | −¥255m |
| Cosmetic Drug And Convenience Storereportable segment | capex | 2022-06-01 → 2023-05-31 | ¥4m |
| Cosmetic Drug And Convenience Storereportable segment | depreciation | 2022-06-01 → 2023-05-31 | ¥44m |
| Cosmetic Drug And Convenience Storereportable segment | revenue | 2022-06-01 → 2023-05-31 | ¥7.8bn |
| Cosmetic Drug And Convenience Storereportable segment | revenue external | 2022-06-01 → 2023-05-31 | ¥7.8bn |
| Cosmetic Drug And Convenience Storereportable segment | segment assets | at 2023-05-31 | ¥1.9bn |
| Cosmetic Drug And Convenience Storereportable segment | segment profit | 2022-06-01 → 2023-05-31 | −¥199m |
| Custody Of Medical Documentsreportable segment | capex | 2022-06-01 → 2023-05-31 | ¥8m |
| Custody Of Medical Documentsreportable segment | depreciation | 2022-06-01 → 2023-05-31 | ¥42m |
| Custody Of Medical Documentsreportable segment | revenue | 2022-06-01 → 2023-05-31 | ¥646m |
| Custody Of Medical Documentsreportable segment | revenue external | 2022-06-01 → 2023-05-31 | ¥646m |
| Custody Of Medical Documentsreportable segment | segment assets | at 2023-05-31 | ¥1.8bn |
| Custody Of Medical Documentsreportable segment | segment profit | 2022-06-01 → 2023-05-31 | ¥81m |
| Dispensing Pharmacyreportable segment | capex | 2022-06-01 → 2023-05-31 | ¥476m |
| Dispensing Pharmacyreportable segment | depreciation | 2022-06-01 → 2023-05-31 | ¥425m |
| Dispensing Pharmacyreportable segment | revenue | 2022-06-01 → 2023-05-31 | ¥42.3bn |
| Dispensing Pharmacyreportable segment | revenue external | 2022-06-01 → 2023-05-31 | ¥42.3bn |
| Dispensing Pharmacyreportable segment | segment assets | at 2023-05-31 | ¥17.5bn |
| Dispensing Pharmacyreportable segment | segment profit | 2022-06-01 → 2023-05-31 | ¥1.7bn |
| Medical Mallreportable segment | capex | 2022-06-01 → 2023-05-31 | ¥0 |
| Medical Mallreportable segment | depreciation | 2022-06-01 → 2023-05-31 | ¥34m |
| Medical Mallreportable segment | revenue | 2022-06-01 → 2023-05-31 | ¥505m |
| Medical Mallreportable segment | revenue external | 2022-06-01 → 2023-05-31 | ¥505m |
| Medical Mallreportable segment | segment assets | at 2023-05-31 | ¥199m |
| Medical Mallreportable segment | segment profit | 2022-06-01 → 2023-05-31 | ¥90m |
| —segment total | capex | 2022-06-01 → 2023-05-31 | ¥489m |
| —segment total | depreciation | 2022-06-01 → 2023-05-31 | ¥547m |
| —segment total | revenue | 2022-06-01 → 2023-05-31 | ¥51.3bn |
| —segment total | revenue external | 2022-06-01 → 2023-05-31 | ¥51.3bn |
| —segment total | segment assets | at 2023-05-31 | ¥21.4bn |
| —segment total | segment profit | 2022-06-01 → 2023-05-31 | ¥1.7bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-06-01 → 2023-05-31 | ¥598m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-06-01 → 2023-05-31 | ¥589m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-06-01 → 2023-05-31 | ¥52.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-06-01 → 2023-05-31 | ¥52.0bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-05-31 | ¥23.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-06-01 → 2023-05-31 | ¥1.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,628
| Item | Context | Value | Unit |
|---|---|---|---|
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.206 | |
| All employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.600 | |
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.782 | |
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.710 | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 1.102 | |
| Gross scope1 greenhouse gas emissions scope1 and2 greenhouse gas emissions | CurrentYearDuration_ConsolidatedAccountingGroupMember | 359 | |
| Gross scope2 greenhouse gas emissions scope1 and2 greenhouse gas emissions | CurrentYearDuration_ConsolidatedAccountingGroupMember | 4510 | |
| Gross scope1 and2 greenhouse gas emissions scope1 and2 greenhouse gas emissions | CurrentYearDuration_ConsolidatedAccountingGroupMember | 4868 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | 20.6 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | 60.0 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row3Member | 78.2 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row4Member | 71.0 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row5Member | 110.2 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | 30.0 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | 50.0 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row3Member | 80.0 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row4Member | 70.0 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row5Member | 100.0 | |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E05379-000DispensingPharmacyReportableSegmentsMember | 9000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_OtherOperatingSegmentsAxisMember | 3000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 683000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E05379-000DispensingPharmacyReportableSegmentsMember | 502000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E05379-000CosmeticDrugAndConvenienceStoreReportableSegmentsMember | 19000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E05379-000CustodyOfMedicalDocumentsReportableSegmentsMember | 22000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E05379-000MedicalMallReportableSegmentsMember | 8000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_OtherReportableSegmentsMember | 129000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 12060381 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 12060381 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 12060381 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 12060381 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | 0 | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 8 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 18 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 82 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 14 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 31 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 13760 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 13913 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | 0 | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 2453 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 793 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 67984 | |
| Number of shares held number of units foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 228 | |
| Number of shares held number of units foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 31 | |
| Number of shares held number of units individuals and others | CurrentYearInstant_OrdinaryShareMember | 49046 | |
| Number of shares held number of units total | CurrentYearInstant_OrdinaryShareMember | 120535 | |
| Number of shares held shares less than one unit | CurrentYearInstant_OrdinaryShareMember | 6881 | |
| Percentage of shareholdings national and local governments | CurrentYearInstant_OrdinaryShareMember | 0.00 | |
| Percentage of shareholdings financial institutions | CurrentYearInstant_OrdinaryShareMember | 0.020 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |